{"id":"W4205563331","doi":"10.2165/00128413-200514820-00086","title":"Health Canada has approved Pfizer's dalteparin sodium [Fragmin],","year":2005,"lang":"en","type":"article","venue":"Inpharma Weekly","topic":"Health and Medical Research Impacts","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"","keywords":"Medicine; Pharmacy; Family medicine; Pharmacology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001297303,0.0002261913,0.0005308416,0.0001229979,0.0002608713,0.00003618894,0.0002109443,0.0001014711,0.0007606929],"category_scores_gemma":[0.0049146,0.0001888434,0.00007122613,0.0003033285,0.0001369299,0.000118649,0.00007166169,0.0008426693,0.0002483315],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001354674,"about_ca_system_score_gemma":0.04674985,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.4203669,"about_ca_topic_score_gemma":0.3174211,"domain_scores_codex":[0.9957457,0.0001332746,0.000562901,0.0003756284,0.001259974,0.00192253],"domain_scores_gemma":[0.9890334,0.0001929656,0.0001089058,0.0004214689,0.0001518261,0.01009146],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002282481,0.0001743124,0.000552984,0.0002670436,0.00002796897,0.000127402,0.0001531818,0.000002229415,0.0005016883,0.00003077578,0.8247365,0.1731977],"study_design_scores_gemma":[0.003298633,0.0003730152,0.00424639,0.0001125811,0.00001370754,0.0001133208,0.00008747899,0.0009546812,0.0016002,0.00001199526,0.9890325,0.000155491],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.08985449,0.001812708,0.000233032,0.8912781,0.0005945967,0.001196297,0.00005127577,0.0001496116,0.01482986],"genre_scores_gemma":[0.8286182,0.000296487,0.0008582877,0.1618672,0.001443086,0.00004919928,0.00006604414,0.00004161794,0.006759878],"genre_candidate":"commentary","genre_consensus":null,"teacher_disagreement_score":0.7387637,"threshold_uncertainty_score":0.9586542,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.131651619425894,"score_gpt":0.4079476999646185,"score_spread":0.2762960805387245,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}